Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 3
2008 4
2009 5
2010 8
2011 7
2012 12
2013 24
2014 17
2015 13
2016 16
2017 16
2018 23
2019 22
2020 25
2021 29
2022 27
2023 25
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.
Xue C, Yang B, Xu J, Zhou C, Zhang L, Gao X, Dai B, Yu S, Mao Z, Mei C, Xu C. Xue C, et al. Clin Kidney J. 2020 Nov 21;14(4):1042-1054. doi: 10.1093/ckj/sfaa191. eCollection 2021 Apr. Clin Kidney J. 2020. PMID: 34094516 Free PMC article. Review.
BACKGROUND: The efficacy and safety of rituximab (RTX) in adult frequent-relapsing (FR) or steroid-dependent (SD) nephrotic syndrome (NS), including minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), are sti …
BACKGROUND: The efficacy and safety of rituximab (RTX) in adult frequent-relapsing (FR) or steroid-dependent …
New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
Basu B, Angeletti A, Islam B, Ghiggeri GM. Basu B, et al. Front Immunol. 2022 Feb 11;13:805697. doi: 10.3389/fimmu.2022.805697. eCollection 2022. Front Immunol. 2022. PMID: 35222385 Free PMC article. Review.
Studies already performed with ofatumumab given in standard doses of 1,500 mg 1.73m(2) suggest no superiority compared to rituximab in children and young adults with steroid dependent nephrotic syndrome. ...In the unique study performed in patie …
Studies already performed with ofatumumab given in standard doses of 1,500 mg 1.73m(2) suggest no superiority compared to rituximab i …
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.
Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Ruggenenti P, et al. J Am Soc Nephrol. 2014 Apr;25(4):850-63. doi: 10.1681/ASN.2013030251. Epub 2014 Jan 30. J Am Soc Nephrol. 2014. PMID: 24480824 Free PMC article. Clinical Trial.
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. ...The mean height z score slope stabi …
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change dise …
Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J. Dossier C, et al. Clin J Am Soc Nephrol. 2023 Dec 1;18(12):1555-1562. doi: 10.2215/CJN.0000000000000288. Epub 2023 Sep 6. Clin J Am Soc Nephrol. 2023. PMID: 37678236
BACKGROUND: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. ...CONCLUSIONS: These results identified low-dose obinituzumab as a promising tr …
BACKGROUND: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or freque …
Vaccines and Disease Relapses in Children with Nephrotic Syndrome.
Angeletti A, Bruschi M, Bianchin S, Bonato I, Montobbio C, Verrina E, Lugani F, Cravedi P, Ghiggeri GM. Angeletti A, et al. Clin J Am Soc Nephrol. 2021 Jun;16(6):937-938. doi: 10.2215/CJN.01890221. Epub 2021 Jun 11. Clin J Am Soc Nephrol. 2021. PMID: 34117084 Free PMC article. Clinical Trial. No abstract available.
Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K; Japanese Study Group of Kidney Disease in Children. Iijima K, et al. J Am Soc Nephrol. 2022 Feb;33(2):401-419. doi: 10.1681/ASN.2021050643. Epub 2021 Dec 8. J Am Soc Nephrol. 2022. PMID: 34880074 Free PMC article. Clinical Trial.
BACKGROUND: Rituximab is the standard therapy for childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome (FRNS/SDNS). ...Moreover, MMF after rituximab reduced the relapse rate and dai …
BACKGROUND: Rituximab is the standard therapy for childhood-onset complicated frequently relapsing or steroid- …
Rituximab vs Low-Dose Mycophenolate Mofetil in Recurrence of Steroid-Dependent Nephrotic Syndrome in Children and Young Adults: A Randomized Clinical Trial.
Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM. Ravani P, et al. JAMA Pediatr. 2021 Jun 1;175(6):631-632. doi: 10.1001/jamapediatrics.2020.6150. JAMA Pediatr. 2021. PMID: 33616641 Free PMC article. Clinical Trial.
This randomized clinical trial examines the superiority of a single dose of rituximab vs low-dose mycophenolate mofetil in preventing the recurrence of steroid-dependent nephrotic syndrome in children and young adults....
This randomized clinical trial examines the superiority of a single dose of rituximab vs low-dose mycophenolate mofetil in preventing …
Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K. Chan EY, et al. J Am Soc Nephrol. 2022 Jun;33(6):1193-1207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30. J Am Soc Nephrol. 2022. PMID: 35354600 Free PMC article.
BACKGROUND: Long-term outcomes after multiple courses of rituximab among children with frequently relapsing, steroid-dependent nephrotic syndrome (FRSDNS) are unknown. ...These findings support repeated rituximab use in FRSD …
BACKGROUND: Long-term outcomes after multiple courses of rituximab among children with frequently relapsing, steroid …
Rituximab for nephrotic syndrome in children.
Iijima K, Sako M, Nozu K. Iijima K, et al. Clin Exp Nephrol. 2017 Apr;21(2):193-202. doi: 10.1007/s10157-016-1313-5. Epub 2016 Jul 15. Clin Exp Nephrol. 2017. PMID: 27422620 Free PMC article. Review.
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition defin …
Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this …
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis.
Kronbichler A, Bruchfeld A. Kronbichler A, et al. Nephron Clin Pract. 2014;128(3-4):277-82. doi: 10.1159/000368590. Epub 2014 Nov 8. Nephron Clin Pract. 2014. PMID: 25401966 Free article. Review.
Treatment of nephrotic syndrome due to minimal change disease and focal segmental glomerulosclerosis remains a challenge since steroid dependence, steroid resistance and a relapsing disease course exhibits a high cumulative steroid dosage. ...A clinical respo …
Treatment of nephrotic syndrome due to minimal change disease and focal segmental glomerulosclerosis remains a challenge since …
228 results